This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Features of Behcet’s disease

Features of Behcet’s disease
Reviewed by Jonathan Chan

1 April 2019 | Jonathan Chan | EYE - Neuro-ophthalmology | imaging, immunology, inflammation, optic erve

This is a retrospective single centre study from Paris, France, between the periods of 1986 to 2015. Twenty-nine out of 217 (13.3%) neuro-Behcet’s disease (NBD) patients presented with neuro-ophthalmic manifestations (55% of men and mean age of 28 years). Sixteen out of 29 patients (55%) had non-parenchymal (NPM) – related signs, and 13/29 (45%) had parenchymal (PM) manifestations. NPM signs included papilloedema due to cerebral venous thrombosis (CVT) in all 16 patients; 6/16 also had sixth nerve palsy. PM signs included papillitis in 7/13 patients, retrobulbar optic neuritis in 4/13 and 2/13 had third nerve palsy. Of the patients, 93.1% had visual symptoms of decreased vision, visual field defects and / or diplopia at initial presentation. All patients received corticosteroids and 79% had immunosuppressive agents – Azathioprine (12 patients), Mycofenolate Mofetil (four patients), Interferon-alpha in three patients, Cyclophosphamide in four patients and Infliximab in one patient. Patients who developed CVT were treated with anticoagulant and Acetazolamide; 66.7% of patients improved or stabilised after treatment and worsened in 33.3%. The mean LogMAR+/-SD visual acuity improved from 0.4+/-0.3 at diagnosis to 0.2+/-0.3 post therapy; 10.3% were legally blind at diagnosis and down to 3.45% after treatment. The authors recommended a multidisciplinary approach including ophthalmologists, neurologists and medical internists for the management of these patients. Early prompt treatment is the key to improve visual outcome of this group of patients.

Neuro-ophthalmological manifestations of Behcet’s disease (NBD).
Alghamdi A, Bodaghi B, Comarmond C, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2019;103:83-7.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency